Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways
Christian P. Larsen(Emory University Hospital), Thomas C. Pearson(Emory Healthcare), Carol Tucker‐Burden(Emory University), Rose Hendrix(Emory Healthcare), Peter S. Linsley(Rosetta Stone (United States)), Eric T. Elwood(Emory University), Alejandro Aruffo(University of Washington Medical Center), Hong Rae Cho(Emory University), Kevin J. Winn(Emory University), Shannon C. Ritchie(Emory University), Diane Z. Alexander(Emory University), Diane Hollenbaugh(Neoleukin Therapeutics (United States))
Cited by 1,466
Related Papers
CTLA-4 is a second receptor for the B cell activation antigen B7.
|The Journal of Experimental Medicine|1991|1.7k
The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome
|Cell|1993|824
4-1BB Costimulatory Signals Preferentially Induce CD8+ T Cell Proliferation and Lead to the Amplification In Vivo of Cytotoxic T Cell Responses
|The Journal of Experimental Medicine|1997|802
Position-specific chemical modification of siRNAs reduces “off-target” transcript silencing
|RNA|2006|785
Rational Development of LEA29Y (belatacept), a High-Affinity Variant of CTLA4-Ig with Potent Immunosuppressive Properties
|American Journal of Transplantation|2005|714